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   Abstract.      Several antimalarials can cause significant prolongation of the electrocardiograph QT interval, which can 
be associated with an increased risk of potentially lethal ventricular arrhythmias. High doses of artemether and artemotil 
have been associated with QT prolongation in dogs, raising the possibility of a class effect with the artemisinin deriva-
tives. Serial electrocardiograms were recorded, and QTc interval was calculated before and after administration of arte-
sunate by intravenous injection in patients with severe falciparum malaria in Bangladesh. Of 21 adult patients with severe 
malaria enrolled, 8 (38%) died. The mean QTc interval was unaffected by bolus intravenous artesunate (2.4 mg/kg). In 
two patients, the QTc interval exceeded 0.5 seconds, but in both cases, an alternative explanation was plausible. No effect 
was observed on the JTc or PR interval, QRS width, blood pressure, or heart rate. Intravenous artesunate does not have 
significant cardiovascular effects in patients with severe   falciparum   malaria.   
    INTRODUCTION 
  Artemisinin-based combination therapies (ACTs) are cur-
rently recommended worldwide as the first-line treatment 
for patients with uncomplicated   falciparum   malaria by the 
World Health Organization (WHO).  1   Parenteral artesunate 
is the treatment of choice for adult patients with severe   fal-
ciparum   malaria. 1,2   This extensive and often unsupervised 
deployment requires an excellent safety profile for this class 
of drugs. Several antimalarial drugs, notably quinidine and 
halofantrine, produce clinically significant delays in ventricu-
lar repolarization, resulting in a prolongation of the electro-
cardiographic QT interval on the electrocardiogram (ECG).  3  
Heterogeneous prolongation of ventricular repolarization pre-
disposes to potentially lethal polymorphic malignant ventricu-
lar tachyarrhythmias (torsades de pointes [TdP]). The belated 
discovery that the antimalarial halofantrine causes marked 
QT prolongation and sudden death,  4   well after its registration 
by several regulatory authorities, has focused attention on the 
potential cardiotoxicity of the antimalarial drugs. Regulatory 
authorities and drug developers have become particularly 
concerned about QT prolongation.  5–8   The artemisinins are 
potent antimalarial drugs that are remarkably well tolerated. 
High intramuscular doses of the oil-based artemether and 
artemotil were associated with significant QT prolongation in 
toxicologic studies conducted in beagle dogs, raising the pos-
sibility of cardiotoxicity with this drug class.  9   Information on 
the electrocardiographic effects of the artemisinin derivatives 
in humans is limited. In clinical studies reporting modest QT 
interval prolongation with the artemisinins, the contributions 
of drug and disease cannot be disentangled, because recovery 
from malaria itself is associated with significant lengthening of 
the QT interval.  3,10   Volunteer studies do not suggest a signifi-
cant cardiovascular effect. We therefore conducted a study on 
the acute effects of high-dose intravenous artesunate on the 
electrocardiographic intervals in patients with severe malaria, 
both on admission and after recovery. 
   MATERIALS AND  METHODS 
    Study site and patients.     This study was conducted at 
Chittagong Medical College Hospital (CMCH), a large 1,000-
bed teaching hospital in Chittagong, Bangladesh. Malaria 
transmission is seasonal and of low intensity in this location. 
The study was part of our studies in severe malaria for which 
ethical approval was obtained from the Medical Research 
Council of Bangladesh. 
  Adult patients (³  16 years old) who had been admitted to 
hospital with a slide-confirmed diagnosis of severe malaria 
according to modified WHO criteria  10   were recruited if they, 
or an attending relative, provided written informed consent. 
Criteria on admission for severe malaria included one or more 
of the following: cerebral malaria (Glasgow Coma Scale [GCS] 
<  11), severe anemia (hematocrit <  20% with parasite count 
>  100,000/µL), jaundice (bilirubin >  3.0 mg/dL with parasite 
count >  100,000/µL), renal failure (serum creatinine >  3 mg/
dL), hypoglycemia (blood glucose < 40 mg/dL), shock (systolic 
blood pressure <  80 mm of Hg with cool extremities), hyper-
parasitemia (peripheral asexual stage parasitemia >  10%), 
hyperlactatemia (venous plasma lactate > 4 mmol/L), and aci-
demia (venous plasma bicarbonate < 15 mmol/L). Pregnant or 
breast-feeding women and any patient who had received any 
cardioactive drugs within 1 week before the start of artesunate 
were excluded from the study. 
   Drug  treatment.     Antimalarial drug treatment was with 
intravenous artesunate (2.4 mg/kg body weight on admis-
sion, followed by 2.4 mg/kg at 12 and 24 hours and then every 
24 hours; Guilin Pharmaceutical Factory, Guangxi, China). 
When the patient was able to take food, treatment was switched 
to oral artemether plus lumefantrine for a further 3 days. 
  Supportive treatments were in accordance with the 2000 
guidelines of the WHO  1   and local hospital guidelines, but the 
availability of renal replacement therapy and mechanical ven-
tilation was limited. 
   Study  procedures.     On admission, a full history and exam-
ination were carried out. Blood samples were obtained for 
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hemoglobin, hematocrit, parasitemia, platelet count, white cell 
count, plasma lactate levels, glucose levels, and full biochem-
istry. Patients were followed up a minimum of once daily until 
discharge, including a full and detailed neurologic examina-
tion where clinically indicated. 
  Serial 12 lead electrocardiograms were performed (elec-
trocardiograph model SE-1; Edan Instruments, Shenzhen, 
China), with a paper speed of 50 mm/s and sensitivity of 20 
mm/mV, immediately followed by a rhythm strip with 10 QRS 
complexes in each of leads II and V2. Time points for record-
ing ECGs were immediately before artesunate administration 
(time 0) and at 10, 30, 60, 120, and 240 minutes after admin-
istration. At each time point, blood pressure, heart rate, and 
aural temperature were measured. Blood was collected on ice 
into fluoride/oxalate tubes at the same time points for assay 
of artesunate and dihydroartemisinin (DHA) plasma concen-
trations. The blood samples were centrifuged at 4°C within 
15 minutes of collection, and the plasma was stored in liquid 
nitrogen until shipment on dry ice to Bangkok, where they 
were stored at −80°C until analysis. This entire procedure was 
performed for every patient for the first dose and in the sub-
set of surviving and cooperative patients for the last dose of 
intravenous artesunate. The decision when to change from 
intravenous to oral antimalarial therapy was determined by 
the treating clinician. 
  The QTc interval was calculated using the mean QT inter-
val, as measured manually over 10 complexes, corrected for 
heart rate using Bazett’s,  11   Fridericia’s, 12   the Framingham,  13  
Hodge’s,  14   and Price’s  15,16   corrections. Bazett’s is the most fre-
quently used but least satisfactory method, whereas Price’s is 
the only method studied specifically in malaria and is thought 
to be the least sensitive to changes in heart rate.  3   The  JTc 
interval was calculated as QTc (Bazett’s correction) minus 
QRS duration. 
  The primary outcome measure of the study was a change 
in QTc interval before and after artesunate. A significant 
change in QTc was defined as an increase in the interval in 
an individual patient after administration of artesunate to 
> 500 ms  17   or by an increase in the mean QTc of all patients 
by > 25%.  4   Secondary outcome measures were other signifi-
cant changes in the ECG including JTc interval and arrhyth-
mias, change in heart rate, and change in systolic blood 
pressure. 
   Drug  measurement.     Concentrations of artesunate and 
DHA in plasma were measured by the Clinical Pharmacology 
Laboratory in the Faculty of Tropical Medicine, Bangkok, by 
high-throughput liquid chromatographic tandem mass spec-
trometry (LC-MS/MS). Plasma samples were analyzed using 
solid-phase extraction (Oasis HLB, µ-elution plate; Waters, 
Milford, MA) and LC-MS/MS. Stable isotope-labeled artesu-
nate and DHA were used as internal standards. Artesunate 
and DHA were quantified using an API 5000 triple quadri-
pole mass spectrometer (Applied Biosystems/MDS SCIEX, 
Foster City, CA), with a TurboV ionization source (TIS) inter-
face operated in the positive ion mode. Quantification was 
performed using selected reaction monitoring (SRM) for the 
transitions m/z 402–267 and 406–163 for artesunate and stable 
labeled artesunate, respectively, and 302–163 and 307–166 for 
DHA and stable labeled DHA, respectively. The liquid chro-
matographic (LC) system was an Agilent 1200 system (Agilent 
Technologies, Santa Clara, CA). Data acquisition and quantifi-
cation were performed using Analyst 1.4 (Applied Biosystems/
MDS SCIEX, Foster City, CA). The performance data for the 
assay during analysis of all samples expressed as coefficients 
of variation (CV%) for quality control samples were <  5% 
throughout the calibration range. 
   Pharmacokinetic  analysis.     Pharmacokinetic analysis of 
the serial plasma artesunate and dihydroartemisinin con-
centrations was performed by non-compartmental analysis 
(NCA) using WinNonlin Version 5 (Pharsight, Mountain View, 
CA). Artesunate was assumed to be converted completely 
  in vivo   into DHA. NCA was performed using the linear/log 
trapezoidal method with extrapolation to time infinity for 
each individual patient using C  LAST / l  Z  , where C  LAST   was 
the final concentration measurement, and l Z   was the termi-
nal elimination slope for each individual patient. The termi-
nal elimination half-life was estimated by log linear regression 
of three to seven observed concentrations. Maximal artesu-
nate and DHA plasma concentrations (C  max  ) and time to 
maximal concentration (T  max  ) were taken directly from the 
observed data. 
   Statistical  analysis.     Analysis was performed by Excel 2007 
and STATA (version 9). Two-sided 95% confidence intervals 
(CIs) were calculated for mean QTc intervals and changes in 
QTc. Means were compared using a paired   t   test. Data were 
transformed to obtain a normal distribution if indicated, 
and correlation coefficients were calculated by the Pearson 
method. We calculated that a minimum of eight patients 
were needed to show an increase in mean QTc of 25% from 
baseline, with significance level (a) of 0.05 and a power (1 − b) 
of 0.90. 
    RESULTS 
  The study was conducted between late July 2006 and August 
2007. In total, 21 adult patients were enrolled, of whom 11 had 
ECGs performed for both first and last doses of artesunate, 
and 10 were studied only after the first dose. The median num-
ber of doses of artesunate received intravenously was four, 
with a range of one to eight doses. Of the 21 patients, 8 (38%) 
died. The median (range) time to death was 36 (2–384) hours. 
Causes of death were deep coma caused by cerebral malaria 
(four patients), acute renal failure (two patients), aspiration 
pneumonia (one patient), and puerperal sepsis (one patient). 
There were no neurologic sequelae. Two surviving patients 
declined to have ECGs after the last dose of intravenous 
artesunate. 
    Baseline characteristics and clinical outcome.     Baseline 
characteristics  are  summarized  in   Tables  1            and   2           .  Coma 
(GCS <  11) was present in 13 patients (62%), and metabolic 
acidosis was common. Two patients (10%) were already 
in hemodynamic shock on admission, but only one patient 
required vasopressor drugs. Other complications dur-
ing admission included acute renal failure (8/21), blackwa-
ter fever (2/21), and aspiration pneumonia (5/21). Three 
patients received a blood transfusion, and 10 patients were 
treated for suspected concomitant septicemia. Patients 
received a median of four doses (mean, 10.1 mg/kg for all 
patients and 11.6 mg/kg for survivors) of intravenous artesu-
nate, followed by oral artemether-lumefantrine twice a day 
for a median of 3 days. 
   QT  interval.      The mean QTc (Bazett) and change before 
and after administration of the first and last doses of intrave-
nous  artesunate  are  shown  in  Table  3 .              The  percentage  changes 128 MAUDE AND OTHERS
are shown in   Figure 1  .   No significant change in the mean 
QTc was observed during the 240-minute observation period 
(  P   > 0.05), independent of the correction method used. Of 
the five QT correction methods used in this study, all showed 
similar patterns of change of QTc over time but with differ-
ent magnitudes. The QTc from Bazett’s correction was con-
sistently the longest, followed in order by Hodges’s, Price’s, 
the Framingham, and Fridericia’s. Although the Fredericia’s 
method is less rate dependent, Bazett’s correction was the 
most sensitive to detect changes in QTc in our dataset. The 
latter method was therefore chosen for use in   Table 3   and 
the figures. 
  No patient had an increase of QTc from baseline of > 25%. 
The mean maximum increase in mean QTc (Bazett) after the 
first dose of artesunate was 5.8 ms (95% CI: 10.4–22.0 ms) at 
120 minutes, and after the last dose, 7.8 ms (95% CI: 11.2–26.8 
ms) at 10 minutes. There was no correlation between the total 
cumulative dose of artesunate or artemisinin received and the 
QTc (using all correction methods). 
  In two patients the QTc (Bazett) exceeded 0.5 seconds 
(  Figure 2A     for patient X and Figure 2B, for patient Y). Only 
Bazett’s correction gave this result for the first doses for these 
patients, but all methods gave this result for the last dose for 
patient X. 
  Patient X, a 28-year-old man, had newly diagnosed perito-
neal tuberculosis, but antituberculous chemotherapy had not 
started at the time of the study. The patient was cachectic with 
a body mass index of 12 kg/m  2 . On admission, the patient was in 
shock with a blood pressure of 70/40 mm of Hg and a tempera-
ture of 39.3°C. Blood pressure was restored to 90/70 mm of Hg 
after a fluid bolus, and the temperature decreased with parac-
etamol to 37.2°C at 4 hours after admission. The QTc (Bazett) 
was 0.415 seconds before the first dose of artesunate and did 
not increase significantly until 2 hours, rising to > 0.5 seconds 
only after 4 hours (0.518 seconds at 4 hours, an increase of 
20%). The heart rate fell from 122 to 104 bpm over the same 
period. The serum potassium during this period remained sta-
ble at 5.1 mmol/L, with slightly low corrected serum calcium 
(8.1 mg/dL) and slightly high serum magnesium (mean, 31.2 
mg/dL) throughout. In addition to artesunate, the patient also 
received one oral dose of 150 mg levamisole, 50 mg ranitidine 
intravenously, and from Days 3 to 5 after admission twice daily 
intravenous ceftriaxone (1 g) and metronidazole (500 mg) for 
suspected aspiration pneumonia. The last dose of intrave-
nous artesunate was given on Day 6 after admission, at which 
time the patient had developed hypokalemia (2.3 mmol/L), 
which was corrected with 40 mmol of intravenous potassium 
 Table 1 
  Baseline characteristics of 21 patients with severe malaria 
Variable
Age, mean years (95% CI) 38.9
(32.9–44.9)
Number of male patients/number of female 
patients
17/4
Days of fever before admission, mean 
(95% CI)
6.12
(3.36–8.87)
Temperature, mean °C (95% CI) 37.6
(37.0–38.3)
Systolic blood pressure, mean mm of Hg 
(95% CI)
113
(99.1–127)
Heart rate, mean beats/min (95% CI) 111
(106–116)
Oxygen saturation, geometric mean % 
(95% CI)
94.2
(92.7–95.7)
Glasgow Coma Score, median (range) 10
(4–15)
Haemoglobin, mean g/dL (95% CI) 9.73
(8.60–10.9)
Peripheral WBC count, mean cells/mm  3  
(95% CI)
7,970
(5,100–10,900)
Platelet count, mean cells/mm  3   (95% CI) 78,100
(33,400–123,000)
Parasitemia, geometric mean parasites/µL 
(95% CI)
125,000
(11,800–239,000)
Serum creatinine level, geometric mean mg/dL 
(95% CI)
1.99
(1.38–2.61)
Serum calcium level, mean mg/dL (95% CI) 8.38
(7.94–8.83)
Serum potassium level, mean mmol/L 
(95% CI)
4.23
(3.74–4.72)
Serum sodium level, mean mmol/L (95% CI) 136
(133–139)
Total serum bilirubin level, geometric mean 
µmol/L (95% CI)
3.77
(0.20–7.35)
Serum albumin, mean g/100 mL (95% CI) 3.09
(2.79–3.40)
Serum aspartate aminotransferase, geometric 
mean U/L (95% CI)
109
(73.7–144)
Serum alanine aminotransferase, geometric 
mean U/L (95% CI)
36.9
(23.1–50.7)
Serum glucose, geometric mean mg/dL 
(95% CI)
115
(68.3–147)
Serum base excess, mean mmol/L (95% CI) −6.95)
(−9.79 to −4.11)
Plasma lactate level, geometric mean mmol/L 
(95% CI)
3.94
(2.68–5.20)
 Table 2 
  Distribution of presenting severity symptoms in patients with severe 
malaria 
Number of patients 
(%) (  N   = 21)
Glasgow Come Scale < 11 13 (61.9)
Haematocrit < 20% with parasite count 
> 100,000/mm  3 
 0 (0)
Bilirubin > 3.0 mg/dL with parasite count 
> 100,000/mm  3 
 2 (9.52)
Serum creatinine > 3.0 mg/dL   5 (23.8)
Systolic blood pressure < 80 mmHg with 
cool extremities
 2 (9.52)
Peripheral asexual stage parasitemia > 5%   3 (14.3)
Venous lactate > 4 mmol/L 11 (52.4)
Venous bicarbonate < 15 mmol/L   7 (33.3)
    NA = not applicable.   
 Table 3 
  Mean (95% CI) QTc (Bazett) and change from baseline after 
artesunate (  P   > 0.05) 
Time post 
dose (min)
First dose Last dose
QTc (ms)
Change in QTc 
from baseline (ms) QTc (ms)
Change in QTc from 
baseline (ms)
0 424 0 422 0
(410–439) NA (391–453) NA
10 414 −10 430 8
(399–429) (−21 to 1) (393–466) (−11 to 27)
30 424 1 424 −4
(409–439) (−13 to 15) (386–462) (−22 to 13)
60 424 1 423 −6
(408–441) (−15 to 17) (400–446) (−27 to 15)
120 429 6 416 −13
(416–443) (−10 to 22) (392–440) (−30 to 4)
240 429 5 415 −14
(412–446) (−10 to 21) (399–431) (−46 to 18)129 ARTESUNATE AND ECG QT INTERVAL IN PATIENTS WITH SEVERE MALARIA
over the first 4 hours plus oral potassium subsequently. 
Twenty-four hours later, the serum potassium had normalized 
at 4.2 mmol/L. The serum calcium and magnesium for this 
patient remained normal during this period. Before the last 
dose of intravenous artesunate on Day 6, the patient had a 
QTc (Bazett) of 0.552 seconds before artesunate administra-
tion, which rose to a maximum of 0.586 seconds 10 minutes 
after injection and fell to 0.411 seconds at 240 minutes after 
dose. The patient’s heart rate rose from 82 to 115 bpm over 
these 4 hours. The prolonged QTc before and after the last 
dose of artesunate was most likely caused by hypokalemia. 
  Patient Y, a 26-year-old man, presented with nonoligu-
ric acute renal failure (creatinine, 5.1 mg/dL) with metabolic 
acidosis (venous pH 7.301; base excess −13 mmol/L) and 
hypokalemia (2.9 mmol/L), which was initially not corrected. 
The QTc (Bazett) was borderline at 0.499 seconds before 
receiving the first dose of artesunate and increased 6% to 
0.531 seconds by 240 minutes after administration of 2.4 mg/kg 
intravenous artesunate. During this period, this patient’s cor-
rected calcium remained normal (mean, 8.8 mg/dL), but serum 
magnesium fell slightly from 26.1 mg/dL at time 0 to 21.3 mg/
dL at 4 hours, and heart rate fell from 110 bpm before artesu-
nate injection to 100 bpm at 4 hours. It is possible this change 
in magnesium, together with hypokalemia, was the cause of the 
prolonged QTc in this patient. The QTc interval had normal-
ized at Day 4 after admission, and serum potassium, calcium, 
and magnesium were normal at this time. Administration of 
artesunate had no effect on the QTc at this time. The patient 
had concomitant bronchopneumonia and cellulitis of the left 
leg and received intravenous ceftriaxone and flucloaxacillin 
from admission until Day 7. Peritoneal dialysis was started 
on Day 2. 
 Figure 2.        QTc as a function of time for patient X (  A  ) and patient 
Y (  B ) .    
 Figure 1.        Percentage change in QTc (Bazett’s correction with 
error bars showing upper and lower 95% confidence intervals) as a 
function of time after administration of the first (  A  ) and last (  B )  doses 
of  intravenous  artesunate.    130 MAUDE AND OTHERS
  At 0.33 (patient X) and 1.39 µg/mL (patient Y), the peak 
levels of artesunate measured in plasma from these two 
patients were below the upper quartile (1.88 µg/mL) of 
the range of values found in this study. This was also true 
for peak DHA levels except after the first dose in patient 
X (3.23 µg/mL; upper quartile, 2.77 µg/mL). Both patients 
survived. 
   Other  ECG  changes.     There were no arrhythmias or 
changes in axis and no significant changes in JT interval, PR 
interval, or QRS duration after administration of either the 
first or last dose of artesunate. A possible extension of this 
study would be to use continuous ambulatory electrocardio-
graphic recording in place of intermittent ECGs. However, 
in light of the negative findings from this study, it is unlikely 
that this will show additional and clinically significant 
cardiotoxicity. 
      Heart rate and blood pressure.     There was no significant 
change in mean heart rate or blood pressure after administra-
tion of either the first or last dose of artesunate. Mean heart 
rate was significantly lower in patients receiving their last 
dose (89.0 bpm; 95% CI, 85.2–92.7 versus 113 bpm; 95% CI, 
109–118;   P   < 0.0001), but mean systolic blood pressure was 
the same throughout (108 mm of Hg; 95% CI, 104–112 versus 
111 mm of Hg; 95% CI, 108–115;   P   = 0.1). This change in heart 
rate was considered related to recovery, a decline in stress, and 
defervescence.  18  
   Artesunate/dihydroartemisinin  pharmacokinetics.    The  esti-
mated  pharmacokinetic  parameters  are  shown  in   Table  4             . 
The overall area under the drug concentration time curve 
(AUC; mean [min–max]) was 41.3 [4.37–216] and 121 µg/mL/
min [32.1–240] for artesunate and dihydroartemisinin, respec-
tively. The percentage of total AUC extrapolated to infinity 
was 3.37% [0.01–63] and 3.85% [0.07–31.9] for artesunate 
and dihydroartemisinin, respectively. The percentage of total 
AUC that was caused by back-extrapolation to estimate ini-
tial concentrations was 68.3% [10.6–96.8] for intravenous arte-
sunate. Observed maximal artesunate and dihydroartemisinin 
plasma concentrations were 1.14 [0.14–4.40] and 2.11 µg/mL 
[0.59–3.76], respectively. Time to maximal concentration was 
11.9 minutes [5.00–60.0] for dihydroartemisinin. There was no 
correlation between the number of doses of drug received and 
the differences in AUC and maximum concentration between 
the first and last dose. 
  There were no significant correlations between the maxi-
mum QTc interval and the maximal plasma concentrations or 
AUC for artesunate, dihydroartemisinin, or the two combined. 
Scatter plots of maximum QTc and maximum increase in QTc 
against peak combined artesunate plus DHA concentration 
are shown in   Figure 3    A and B. 
    DISCUSSION 
 Although  Plasmodium falciparum  sequesters in the myocar-
dial microvasculature, significant myocardial dysfunction or 
arrhythmias caused by the disease are very unusual in severe 
malaria. The quinoline antimalarials all have potent cardio-
vascular effects, but the effects of the artemisinin derivatives 
have been unclear. This study evaluated the effects of intra-
venous artesunate on the ECG in patients treated for severe 
malaria. Artesunate is given as a bolus injection, so very high 
blood levels occur at the end of the injection and the effects 
on cardiac conduction times can be assessed over a short time 
period, relatively independent of the changes in disease state. 
Even allowing for some hysteresis, resulting from equilibra-
tion from plasma to cardiac myocyte, these very high plasma 
concentrations would be expected to be associated with the 
greatest cardiovascular effects. However, there were no con-
sistent cardiovascular or electrocardiographic effects after 
artesunate injection. In the acute phase of malaria, the QTc 
is commonly short because of increased sympathetic tone 
from arousal, stress, discomfort, anxiety, and usually fast-
ing and elongates with recovery when the patient is relaxed, 
comfortable, supine in bed, and has often resumed eating. 
 Figure 3.        Maximum QTc (Bazett) (  A  ) and maximum increase in 
QTc (Bazett) (  B  ) as a scatter plot against maximum combined artesu-
nate plus DHA concentration for each patient.       
 Table 4 
  Pharmacokinetics of dihydroartemisinin (DHA) and artesunate 
shown as mean (95% CI) maximal observed plasma concentration 
(C  max  ) and predicted area under the drug concentration time curve 
extrapolated to infinity (AUC) 
Dose
DHA Artesunate
C  max   (µg/mL) AUC (µg/mL/min) C  max  (µg/mL) AUC (µg/mL/min)
First 2.06 121 1.02 45.1
(1.70–2.43) (90.7–152) (0.584–1.46) (18.5–71.7)
Last 2.29 136 1.37 30.7
(1.93–2.64) (94.4–178) (0.390–2.34) (13.4–48.1)131 ARTESUNATE AND ECG QT INTERVAL IN PATIENTS WITH SEVERE MALARIA
This relative QT prolongation has often been wrongly attrib-
uted to the effects of antimalarial drugs.  3   Indeed, nearly 
all studies of antimalarial drugs (including sulfadoxine-
pyrimethamine, which has no cardiac activity at all) report 
some prolongation of the QT interval in the days after the 
start of treatment.  3   In this study, the QTc interval was unaf-
fected by high doses of intravenous artesunate. There was no 
correlation between plasma levels of artesunate or its active 
metabolite dihydroartemisinin with QTc or the percentage 
increase in QTc. In addition, no effect was observed on the JTc 
or PR interval, QRS width, blood pressure, or heart rate. 
  There are many reasons underlying fluctuation in the QT 
interval in the acute phase of managing a life-threatening dis-
ease. In two patients, the QTc increased > 0.5 seconds. In one 
of these, the QTc was prolonged before the administration 
of artesunate and was related to hypokalemia. In the second 
patient, QTc did increase slightly after the administration of 
artesunate on admission. Because the QTc prolongation was 
not detected until 120 minutes after drug administration at a 
time that the artesunate and DHA concentrations had fallen 
to 0% and 18.7% of the respective peak values, and no change 
in QTc was detected at 10, 30, and 60 minutes, when DHA plus 
artesunate concentrations were 4.62, 2.82, and 1.71 µg/mL,
it is unlikely that the QTc prolongation was caused by the 
artemisinins, even when assuming some degree of hystere-
sis in the system. Other drugs were also administered to this 
patient and together with defervescence during the observa-
tion period could have contributed to the prolongation in QTc 
time. It should be noted that administration of the same dose 
of artesunate to the same patient after recovery was associ-
ated with a decrease, rather than an increase, in QTc time, and 
in some other patients, QT decreased immediately after arte-
sunate injection. 
  Of the antimalarial drugs, the quinolines, quinine, quini-
dine, chloroquine, and halofantrine, can cause significant pro-
longation of the QT interval. QT prolongation by 25% occurs 
in ~10% of patients given high-dose intravenous quinine.  10,19  
Halofantrine induces consistent dose-dependent prolongation 
of the QTc interval, and its use in patients with malaria has 
been associated with arrhythmias and sudden death.  4  Although 
no longer recommended for the treatment of uncomplicated 
  falciparum   malaria in the absence of close cardiac monitor-
ing, it is still available on the market. Most information on the 
cardiovascular effects, including ECG changes, of the artemisi-
nin drugs are on the fat-soluble derivatives artemether and 
arteether, which have considerably longer plasma clearance 
times than water-soluble artesunate. In beagle dogs and rats, 
prolonged administration of high doses of artemether and 
arteether induced neurotoxicity, which was asso  ciated with 
a prolongation of the QT interval on the ECG.  9,20,21   It is not 
clear, however, whether the effects on the ECG were a result of 
direct cardiotoxicity or were an indirect result of concomitant 
central nervous system toxicity. In a large randomized compar-
ison of high-dose artemether and quinine in adults with severe 
malaria, serial ECGs were recorded in 301 patients. Slight 
QT prolongation was noted in both groups, 11 of 152 (7%) 
artemether recipients and 12 of 133 (9%) quinine recipients 
had an increase of > 25%.  10   Neurotoxicity was not shown. 
There were no dysrhythmias or adverse cardiovascular effects 
in this study. The effects of recovery from severe malaria and 
any drug activity on ventricular repolarization could not be 
distinguished. Studies on oral administration of artemether, 
including in combination with lumefantrine, to both malaria 
patients and healthy volunteers did not show any significant 
electrocardiographic abnormalities including evidence of 
QTc prolongation.  18,22–25   Compared with artemether and arte-
mether, artesunate has a more favorable toxicity profile, even 
though plasma concentrations of the parent compound and the 
common metabolite DHA after intravenous injection are an 
order of magnitude higher. Considerably higher doses of arte-
sunate are needed to produce neurotoxicity in animals.  9,26,27  
No effects on the ECG in dogs receiving the equivalent of the 
standard human dose of 2.4 mg/kg intravenous artesunate was 
observed.  28   Doses several orders of magnitude higher than 
those used to treat malaria were required to cause negative 
inotropy in isolated guinea pig heart  29   and hypotension in rab-
bits,  28   all suggesting a very wide therapeutic ratio, and this is in 
line with the negative findings in this study. 
 In conclusion, this study showed that intravenous artesunate 
does not have significant cardiovascular effects in patients 
with severe   falciparum   malaria. High-dose intravenous arte-
sunate does not prolong the QT interval. 
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